Grant ID CP120017
Awarded On March 29, 2012
Title Clinically Actionable Mutation Profiling for Cancer Personalized Medicine using Scalable, Ultra-deep Next Generation Sequencing
Program Product Development Research
Award Mechanism Company Commercialization
Institution/Organization Asuragen, Inc.
Principal Investigator/Program Director Gary Latham
Cancer Sites All Sites
Contracted Amount $6,837,265
Lay Summary

We propose to establish targeted next generation sequencing (NGS) assays that enable accurate, sensitive, and cost-effective detection of “actionable” mutations in clinically relevant, cancer-related genes. The existing armament of anticancer drugs includes ~100 approved therapies, and an additional 800 drugs in development. The NGS assays will interrogate mutations in key cancer pathways relevant to these medicines, and both improve the diagnostic yield of “real world” clinical biopsies and help steer drugs to those patients that are most likely to benefit. The funding for this proposal will help bridge the gap between the identified clinical utility of mutations and the need for clinical ...

Read More